Literature DB >> 1965423

Prognostic value of response to chemotherapy using ultrasound in lung cancer with metastatic liver involvement.

C Görg1, W B Schwerk, M Wolf, K Havemann.   

Abstract

Between January 1981 and December 1989, a total of 205 patients with lung cancer were treated in different multicenter trials in our hospital. In 130 cases, small cell lung cancer (SCLC), and in 75 cases, non-small cell lung cancer (NSCLC) was diagnosed. Abdominal sonography for pretreatment staging revealed liver metastasis in 59 patients (42 SCLC, 17 NSCLC), sonographic patterns of liver metastasis were described and the prognostic significance of evaluation of response according to abdominal ultrasound after the first two cycles of treatment was investigated. For both histological types of lung cancer, the hypoechoic or isoechoic (80%), small noduled (97%) liver metastasis with multifocal spread (86%) was found to be typical. Sonographic follow-up examinations for liver metastasis were performed in 46 patients (35 SCLC, 11 NSCLC), and 134 chemotherapy cycles. Response to chemotherapy according to abdominal ultrasound was seen in only 3 out of 11 patients with NSCLC (27%) and 17 out of 35 with SCLC (49%). Best response was achieved after the first two cycles with only 6 patients (6 SCLC, 0 NSCLC) exhibiting complete liver metastasis remission. All other patients exhibited on ultrasound a progressive or non-responsive illness. In summary, sonography is reliable with respect to the diagnosis and follow-up examination of liver metastases in lung cancer. A lack of metastasis regression subsequent to the first two cycles of therapy is associated with poor prognosis and continued treatment cannot be justified in such patients.

Entities:  

Mesh:

Year:  1990        PMID: 1965423

Source DB:  PubMed          Journal:  Bildgebung        ISSN: 1012-5655


  4 in total

1.  Specific organ metastases and survival in metastatic non-small-cell lung cancer.

Authors:  Tomohiro Tamura; Koichi Kurishima; Kensuke Nakazawa; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2014-09-04

2.  Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.

Authors:  Ying Cheng; Qiming Wang; Kai Li; Jianhua Shi; Lin Wu; Baohui Han; Gongyan Chen; Jianxing He; Jie Wang; Haifeng Qin; Xiaoling Li
Journal:  Cancer Med       Date:  2021-12-23       Impact factor: 4.452

3.  Serum Alkaline Phosphatase in Cryptogenic Stroke Cases with Active Cancer.

Authors:  Tesseki Izumi; Hitoki Nanaura; Naohiko Iguchi; Maki Ozaki; Kazuma Sugie
Journal:  Intern Med       Date:  2022-03-01       Impact factor: 1.271

4.  Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer

Authors:  Özgür Önal; Murat Koçer; Hande Nur Eroğlu; Servet Derya Yilmaz; Ismet Eroğlu; Dilek Karadoğan
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.